Eli Lilly and Company, Thermo Fisher Scientific, and Gilead Sciences are the three Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies involved in the research, development, manufacturing and marketing of prescription drugs and therapies. Investors in these equities gain exposure to a sector characterized by high research and development costs, stringent regulatory approval processes and patent-driven revenue cycles. Because drug trial results, regulatory decisions and patent expirations can all cause sharp price movements, pharmaceutical stocks often display higher volatility and event-driven risk compared with many other industries. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Shares of LLY stock traded up $17.08 during mid-day trading on Friday, hitting $701.51. 8,211,278 shares of the stock traded hands, compared to its average volume of 6,346,453. The stock has a market cap of $663.95 billion, a P/E ratio of 45.85, a P/E/G ratio of 0.95 and a beta of 0.44. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The stock's fifty day moving average is $764.55 and its two-hundred day moving average is $794.69. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $972.53.
Read Our Latest Research Report on LLY
Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
TMO traded up $4.92 during trading on Friday, reaching $489.96. 2,462,453 shares of the company's stock were exchanged, compared to its average volume of 3,069,315. The stock has a market capitalization of $185.01 billion, a P/E ratio of 28.34, a price-to-earnings-growth ratio of 2.59 and a beta of 0.74. Thermo Fisher Scientific has a 1 year low of $385.46 and a 1 year high of $627.88. The company's fifty day simple moving average is $434.83 and its 200-day simple moving average is $460.79. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50.
Read Our Latest Research Report on TMO
Gilead Sciences (GILD)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Gilead Sciences stock traded down $0.65 during trading on Friday, reaching $118.37. The company had a trading volume of 8,859,738 shares, compared to its average volume of 6,401,320. The firm has a market capitalization of $146.87 billion, a PE ratio of 23.58, a price-to-earnings-growth ratio of 0.73 and a beta of 0.33. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. Gilead Sciences has a 1-year low of $72.89 and a 1-year high of $121.83. The firm's 50-day simple moving average is $111.88 and its 200 day simple moving average is $108.33.
Read Our Latest Research Report on GILD
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
MarketBeat All Access